Kenneth Pienta - Mar 25, 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Kenneth Pienta by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Mar 25, 2022
Transactions value $
$0
Form type
4
Date filed
3/29/2022, 04:12 PM
Previous filing
Dec 21, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +40K $0.00 40K Mar 25, 2022 Common Stock 40K $5.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022.